Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Although statins and other pharmacological approaches have improved the management of lipid abnormalities, there exists a need for newer treatment modalities especially for the management of hypertriglyceridemia. Lipoprotein lipase (LPL), by promoting hydrolytic cleavage of the triglyceride core of lipoproteins, is a crucial node in the management of plasma lipid levels. Although LPL expression and activity modulation is observed as a pleiotropic action of some the commonly used lipid lowering drugs, the deliberate development of drugs targeting LPL has not occurred yet. In this review, we present the biology of LPL, highlight the LPL modulation property of currently used drugs and review the novel emerging approaches to target LPL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Schoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071 · cited 1×
“The carriers of any of the four APOC3 mutations were found to be at 40% lower risk for coronary heart disease [126].”
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688 · cited 2×
“In a GWAS published in 2008, Pollin et al. uncovered the cardioprotective effect of APOC3 in the Lancaster Amish population among carriers of the null mutation in the APOC3 gene [62].”
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Mandard, S., Zandbergen, F., van Straten, E., Wahli, W., Kuipers, F., Müller, M., & Kersten, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m506519200 · Cited by 433
Staels, B., Vu-Dac, N., Kosykh, V. A., Saladin, R., Fruchart, J. C., Dallongeville, J., & Auwerx, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117717 · Cited by 410 · cited 1×
“Particularly, fibrates inhibit the expression of APOC-III thereby enhancing the LPL activity [82].”
Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377 · cited 1×
“The first studies on volanesorsen emerged in 2013, when the identification of this antisense oligo was reported from a screen of ~350 MOE chimeric candidates [131].”
Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance
Park, Y., & Harris, W. S. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m200282-jlr200 · Cited by 348
Wong, H., & Schotz, M. C. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200007-jlr200 · Cited by 298
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2008) · Clinical Science · doi:10.1042/cs20070308 · Cited by 282 · cited 1×
“APOC3 is found on APOB-containing lipoproteins like VLDL and LDL but unlike APOB is much smaller (only ~9 Kda) [63].”
Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia.
Péterfy, M., Ben-Zeev, O., Mao, H. Z., Weissglas-Volkov, D., Aouizerat, B. E., Pullinger, C. R., Frost, P. H., Kane, J. P., Malloy, M. J., Reue, K., et al. (2007) · Nature Genetics · doi:10.1038/ng.2007.24 · Cited by 226
Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523219 · Cited by 201
Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion
Wang, Y., Gusarova, V., Banfi, S., Gromada, J., Cohen, J. C., & Hobbs, H. H. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054882 · Cited by 189
Lessons learned from the clinical development and market authorization of Glybera
Bryant, L. M., Christopher, D. M., Giles, A. R., Hinderer, C., Rodriguez, J. L., Smith, J. B., Traxler, E. A., Tycko, J., Wojno, A. P., & Wilson, J. M. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.087 · Cited by 189 · cited 1×
“The clinical trials of alipogene tiparvovec in 27 patients with LPL deficiency showed a transient reduction in plasma TG levels [121].”
Gene therapy for lipoprotein lipase deficiency
Gaudet, D., Méthot, J., & Kastelein, J. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283555a7e · Cited by 178 · cited 1×
“A gene therapy designed to introduce extra copies of the functional potent enzyme in the muscles of the lower limbs of patients was introduced in Europe in 2014 [116,117].”
Digenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0126 · Cited by 170 · cited 1×
“In a recent report, the efficacy of volanesorsen in improving insulin sensitivity was demonstrated in type 2 diabetes patients [136].”
Carpentier, A. C., Frisch, F., Labbé, S. M., Gagnon, R., de Wal, J., Greentree, S., Petry, H., Twisk, J., Brisson, D., & Gaudet, D. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3002 · Cited by 165 · cited 1×
“Although the plasma TG levels rebounded to pre-treatment levels in 26 weeks after alipogene administration, the therapy was found to have a long term impact on chylomicron metabolism with a reduction in chylomicron TG content [122].”
Lipoprotein Lipase S447X: A Naturally Occurring Gain-of-Function Mutation
Rip, J., Nierman, M. C., Ross, C. J., Jukema, J. W., Hayden, M. R., Kastelein, J. J. P., Stroes, E. S. G., & Kuivenhoven, J. A. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000219283.10832.43 · Cited by 157
Rensen, P. C. N., & van Berkel, T. J. C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.14791 · Cited by 144 · cited 1×
“As opposed to APOC2 and APOA5, APOC1, APOC3 and APOE inhibit LPL-dependent TG clearance [58–61].”
Wang, H., Astarita, G., Taussig, M. D., Bharadwaj, K. G., DiPatrizio, N. V., Nave, K.-A., Piomelli, D., Goldberg, I. J., & Eckel, R. H. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2010.12.006 · Cited by 139 · cited 2×
“Tissue-specific LPL knockout and overexpression have facilitated a detailed understanding of LPL functions [32,49–51].”
Ferreira, V., Twisk, J., Kwikkers, K., Aronica, E., Brisson, D., Methot, J., Petry, H., & Gaudet, D. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.169 · Cited by 137
Wyler von Ballmoos, M. C., Haring, B., & Sacks, F. M. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.05.002 · Cited by 134
Yang, X., Lee, S.-R., Choi, Y.-S., Alexander, V. J., Digenio, A., Yang, Q., Miller, Y. I., Witztum, J. L., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m066399 · Cited by 103 · cited 1×
“Using a novel high-throughput chemiluminescent ELISA, authors reported a decrease in APOC3 associated with specific lipoproteins [135].”
Angiopoietin-like Protein 4 Inhibition of Lipoprotein Lipase
Lafferty, M. J., Bradford, K. C., Erie, D. A., & Neher, S. B. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.497602 · Cited by 88
The acidic domain of GPIHBP1 is important for the binding of lipoprotein lipase and chylomicrons.
Gin, P., Yin, L., Davies, B. S. J., Weinstein, M. M., Ryan, R. O., Bensadoun, A., Fong, L. G., Young, S. G., & Beigneux, A. P. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802579200 · Cited by 85 · cited 1×
“A small glyco-protein, GPIHBP1 has high affinity for LPL and has recently been shown to be responsible for the transendothelial transport of LPL from the parenchymal cells to the capillary lumen where it is postulated to provide a platform for lipolysis [25–27].”
Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83 · cited 1×
“The triglyceride-lowering property of statins is often inadequate in cases of severe hypertriglyceridemia and requires supplementation with fibrates, niacin or omega 3 fatty acids [87].”
Localization of lipoprotein lipase mRNA in selected rat tissues
Goldberg, I. J., Soprano, D. R., Wyatt, M. L., Vanni, T. M., Kirchgessner, T. G., & Schotz, M. C. (1989) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38241-9 · Cited by 77
Gong, H., Dong, W., Rostad, S. W., Marcovina, S. M., Albers, J. J., Brunzell, J. D., & Vuletic, S. (2013) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413505601 · Cited by 51 · cited 1×
“Immunostaining for LPL has been detected in the neurons, astrocytes, microglia and oligo-dendroglia throughout the central nervous system [31].”
Park, Y., Jones, P. G., & Harris, W. S. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.1.45 · Cited by 41
Ohira, M., Endo, K., Saiki, A., Miyashita, Y., Terai, K., Murano, T., Watanabe, F., Tatsuno, I., & Shirai, K. (2012) · Metabolism · doi:10.1016/j.metabol.2012.03.010 · Cited by 25
Cited by
Microbial lipases and their industrial applications: a comprehensive review
Chandra, P., Enespa, Singh, R., & Arora, P. K. (2020) · Microbial Cell Factories · doi:10.1186/s12934-020-01428-8 · Cited by 887
Azzu, V., Vacca, M., Virtue, S., Allison, M., & Vidal-Puig, A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.054 · Cited by 369
Richardson, T. G., Leyden, G. M., Wang, Q., Bell, J. A., Elsworth, B., Davey Smith, G., & Holmes, M. V. (2022) · PLOS Biology · doi:10.1371/journal.pbio.3001547 · Cited by 304
Du, Z., & Qin, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010363 · Cited by 140
“The lower activity or levels of LPL can cause increased concentrations of triglyceride and triglyceride-rich lipoproteins [27].”
BackgroundKristensen, K. K., Leth-Espensen, K. Z., Mertens, H. D. T., Birrane, G., Meiyappan, M., Olivecrona, G., Jørgensen, T. J. D., Young, S. G., & Ploug, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920202117 · Cited by 72
Metadata
- Authors
- Geldenhuys, W. J., Lin, L., Darvesh, A. S., & Sadana, P.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 22
- Issue
- 2
- Pages
- 352-365
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2534990463
- Cited by
- 64
- References
- 32
- FWCI
- 4.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.